From 1 ratings within the last 6 months. This is not an investment recommendation.
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive dysfunction. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine design to target neutral system, such as focus, interference processing, and multitasking; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company is headquartered in Boston, Massachusetts.